Su-Jin Park

List of Publications by Year
in descending order

52 papers	2,799 citations	304743 22 h-index	197818 49 g-index
54 all docs	54 docs citations	54 times ranked	6123 citing authors

#	Article	IF	Citations
1	Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerging Microbes and Infections, 2021, 10, 152-160.	6.5	54
2	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	12.8	224
3	Molecular Signatures of Inflammatory Profile and B-Cell Function in Patients with Severe Fever with Thrombocytopenia Syndrome. MBio, 2021, 12, .	4.1	25
4	Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. Nature Communications, 2021, 12, 4567.	12.8	43
5	Development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thermal inactivation method with preservation of diagnostic sensitivity. Journal of Microbiology, 2020, 58, 886-891.	2.8	28
6	Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea. Frontiers in Microbiology, 2020, 11, 587613.	3.5	8
7	Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clinical Microbiology and Infection, 2020, 26, 1520-1524.	6.0	180
8	Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 2268.	2.4	106
9	Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host and Microbe, 2020, 27, 704-709.e2.	11.0	815
10	Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus (SFTSV) in South Korea. JCI Insight, 2020, 5, .	5.0	58
11	Greater Efficacy of Black Ginseng (CJ EnerG) over Red Ginseng against Lethal Influenza A Virus Infection. Nutrients, 2019, 11, 1879.	4.1	18
12	Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infectious Diseases, 2019, 19, 676.	2.9	144
13	Shedding and Transmission Modes of Severe Fever With Thrombocytopenia Syndrome Phlebovirus in a Ferret Model. Open Forum Infectious Diseases, 2019, 6, .	0.9	14
14	Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Phlebovirus in Domesticated Deer in South Korea. Virologica Sinica, 2019, 34, 501-507.	3.0	4
15	Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets. Nature Communications, 2019, 10, 3836.	12.8	51
16	Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets. Journal of Microbiology, 2019, 57, 163-169.	2.8	3
17	Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26900-26908.	7.1	25
18	A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus. MBio, 2019, 10, .	4.1	10

#	Article	IF	Citations
19	Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis. Nature Microbiology, 2019, 4, 429-437.	13.3	46
20	Ferret animal model of severe fever with thrombocytopenia syndrome phlebovirus for human lethal infection and pathogenesis. Nature Microbiology, 2019, 4, 438-446.	13.3	66
21	Comparison of the virulence and transmissibility of canine H3N2 influenza viruses and characterization of their canine adaptation factors. Emerging Microbes and Infections, 2018, 7, 1-14.	6.5	14
22	Comparison of the pathogenic potential of highly pathogenic avian influenza (HPAI) H5N6, and H5N8 viruses isolated in South Korea during the 2016â€“2017 winter season. Emerging Microbes and Infections, 2018, 7, 1-10.	6.5	32
23	Altered virulence of Highly Pathogenic Avian Influenza (HPAI) H5N8 reassortant viruses in mammalian models. Virulence, 2018, 9, 133-148.	4.4	13
24	Epidemiology of severe fever and thrombocytopenia syndrome virus infection and the need for therapeutics for the prevention. Clinical and Experimental Vaccine Research, 2018, 7, 43.	2.2	47
25	Evaluation of two different enzyme-linked immunosorbent assay for severe fever with thrombocytopenia syndrome virus diagnosis. Clinical and Experimental Vaccine Research, 2018, 7, 82.	2.2	3
26	Seroprevalence and genetic characterization of severe fever with thrombocytopenia syndrome virus in domestic goats in South Korea. Ticks and Tick-borne Diseases, 2018, 9, 1202-1206.	2.7	21
27	Pathogenicity and genetic characterisation of a novel reassortant, highly pathogenic avian influenza (HPAI) H5N6 virus isolated in Korea, 2017. Eurosurveillance, 2018, 23, .	7.0	19
28	Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness. Journal of Microbiology and Biotechnology, 2018, 28, 997-1006.	2.1	15
29	Walled-off Pancreatic necrosis in a Dog. Journal of Veterinary Clinics, 2018, 35, 146-149.	0.1	2
30	Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. Journal of Virology, 2017, 91, .	3.4	18
31	Rapid acquisition of polymorphic virulence markers during adaptation of highly pathogenic avian influenza H5N8 virus in the mouse. Scientific Reports, 2017, 7, 40667.	3.3	13
32	Genetic and phylogenetic characterizations of a novel genotype of highly pathogenic avian influenza (HPAI) H5N8 viruses in 2016/2017 in South Korea. Infection, Genetics and Evolution, 2017, 53, 56-67.	2.3	23
33	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	3.4	10
34	Molecular genomic characterization of tick- and human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea. PLoS Neglected Tropical Diseases, 2017, 11, e0005893.	3.0	54
35	Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. Eurosurveillance, 2017, 22, .	7.0	44
36	Injectable and Pathogenâ€Mimicking Hydrogels for Enhanced Protective Immunity against Emerging and Highly Pathogenic Influenza Virus. Small, 2016, 12, 6279-6288.	10.0	8

#	Article	IF	Citations
37	Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology, 2016, 498, 36-43.	2.4	16
38	Genetic diversity and pathogenic potential of low pathogenic H7 avian influenza viruses isolated from wild migratory birds in Korea. Infection, Genetics and Evolution, 2016, 45, 268-284.	2.3	10
39	Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Archives of Virology, 2016, 161, 2749-2764.	2.1	11
40	Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea. Clinical Infectious Diseases, 2016, 62, 755-760.	5.8	165
41	Growth and Pathogenic Potential of Naturally Selected Reassortants after Coinfection with Pandemic H1N1 and Highly Pathogenic Avian Influenza H5N1 Viruses. Journal of Virology, 2016, 90, 616-623.	3.4	4
42	Dynamic changes in host gene expression associated with H5N8 avian influenza virus infection in mice. Scientific Reports, 2015, 5, 16512.	3.3	40
43	Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets. Scientific Reports, 2015, 5, 15940.	3.3	20
44	Evaluation of the zoonotic potential of a novel reassortant H1N2 swine influenza virus with gene constellation derived from multiple viral sources. Infection, Genetics and Evolution, 2015, 34, 378-393.	2.3	11
45	Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors. Journal of Virology, 2015, 89, 287-299.	3.4	54
46	Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine. Clinical and Experimental Vaccine Research, 2014, 3, 194.	2.2	7
47	Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. Journal of General Virology, 2014, 95, 793-798.	2.9	15
48	Pathobiological features of a novel, highly pathogenic avian influenza A(H5N8) virus. Emerging Microbes and Infections, 2014, 3, 1-13.	6.5	106
49	Avian-derived NS gene segments alter pathogenicity of the A/Puerto Rico/8/34 virus. Virus Research, 2014, 179, 64-72.	2.2	3
50	Adjuvant efficacy of mOMV against avian influenza virus infection in mice. Journal of Microbiology, 2013, 51, 682-688.	2.8	2
51	Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production. Journal of General Virology, 2013, 94, 1230-1235.	2.9	20
52	Virulence and Genetic Compatibility of Polymerase Reassortant Viruses Derived from the Pandemic (H1N1) 2009 Influenza Virus and Circulating Influenza A Viruses. Journal of Virology, 2011, 85, 6275-6286.	3.4	51